A high level of FOXM1 expression detectable by immunohistochemistry was found in ~85% cases of diffuse large B-cell lymphoma, and pharmacologic inhibition of FOXM1 in lymphoma cell lines substantially decreased invasiveness in vitro, which correlated with a reduction in expression of Ki-67 and two epithelial-to-mesenchymal transition markers (MMP-2 and MMP-9) [31]. The gene discussed is MMP9; the disease is diffuse large B-cell lymphoma.